Cancer Biology and Carcinogenesis

Cancer is not one disease but a family of hundreds, united by a single deep idea: it is a disorder of cells that have escaped the rules governing normal growth, differentiation, and death. Understanding how a normal cell becomes malignant — and why it behaves the way it does at the bedside — is the intellectual backbone of all of oncology. Every drug you will ever prescribe, every screening test you order, and every prognosis you give traces back to the biology on this page.

This topic ties together genetics, cell biology, and clinical medicine. If you grasp the hallmarks of cancer and the logic of oncogenes and tumor suppressors, the rest of oncology — from why targeted therapies work to why cancers relapse — becomes reasoning rather than memorization.

Learning Objectives

• Explain the somatic-mutation theory and the modern "hallmarks of cancer" framework.
• Distinguish oncogenes from tumor suppressor genes, including their mechanisms and inheritance patterns.
• Describe multistep carcinogenesis (initiation, promotion, progression) with concrete examples.
• Outline the invasion–metastasis cascade and why metastasis, not the primary tumor, usually kills.
• Connect molecular concepts to real clinical decisions: targeted therapy, screening, and hereditary cancer risk.
• Recognize and correct the most common misconceptions students hold about cancer causation.

Quick Answer

Cancer arises when a single cell accumulates enough genetic and epigenetic changes to grow uncontrollably, resist death, and eventually invade and spread. These changes fall into two functional classes: activating mutations in oncogenes (accelerators, one hit is enough) and inactivating mutations in tumor suppressor genes (brakes, usually needing both copies lost). Hanahan and Weinberg distilled the shared behaviors of cancer into the hallmarks of cancer — including sustained proliferation, evasion of growth suppressors, resistance to apoptosis, replicative immortality, angiogenesis, and activating invasion and metastasis. Carcinogenesis is multistep, unfolding over years through initiation, promotion, and progression. The lethal step for most patients is metastasis, the multistage escape of tumor cells to distant organs. This somatic-mutation and hallmarks model replaced older humoral and purely infectious theories over the twentieth century.

Where It Came From

For most of medical history, cancer had no coherent mechanism. The ancient Greeks, following Hippocrates and later Galen, explained tumors through the humoral theory: cancer was an excess of "black bile" (melancholia) stagnating in tissue. The word cancer itself comes from the Greek karkinos (crab), reportedly because the swollen veins around a breast tumor reminded observers of a crab's legs. This theory held for nearly two thousand years and, crucially, discouraged surgery — if cancer was a systemic humoral imbalance, cutting out a lump made no sense.

The humoral model began to crack in the seventeenth and eighteenth centuries as anatomists and pathologists examined actual tissue. The real turning point came with the cell theory. In 1858 Rudolf Virchow declared omnis cellula e cellula — every cell comes from a cell — and argued that cancer, too, arose from cells, specifically from abnormal cell division. This reframed cancer as a local cellular disease, not a floating humor, and made surgery rational.

The next question was what makes a cell go wrong? Several clues converged. In 1775 the surgeon Percivall Pott noticed an epidemic of scrotal cancer in chimney sweeps and linked it to soot — the first identification of an environmental carcinogen and the birth of cancer epidemiology. In 1911 Peyton Rous showed that a virus could transmit a sarcoma between chickens, proving that a transmissible agent could cause cancer (the Rous sarcoma virus, later Nobel-recognized). By the mid-twentieth century, radiation and chemical carcinogens were shown to cause mutations, suggesting DNA damage was central.

The decisive synthesis was the somatic-mutation theory: cancer is driven by mutations in the DNA of body (somatic) cells. This crystallized in the 1970s–80s when the src gene of Rous sarcoma virus was found to be a corrupted copy of a normal cellular gene (J. Michael Bishop and Harold Varmus, Nobel 1989) — proving cancer genes are hijacked versions of our own growth genes (proto-oncogenes). Around the same time, Alfred Knudson's 1971 statistical analysis of retinoblastoma produced the two-hit hypothesis, predicting the existence of tumor suppressor genes. Finally, in 2000 (updated 2011 and 2022), Douglas Hanahan and Robert Weinberg published The Hallmarks of Cancer, organizing the chaos of cancer biology into a small set of shared acquired capabilities — the framework that now structures how the entire field thinks.

The Hallmarks of Cancer

Hanahan and Weinberg argued that however diverse cancers look, nearly all acquire the same underlying capabilities on the road to malignancy. The core hallmarks are:

1. Sustaining proliferative signaling — cancer cells make their own "grow" signals or keep growth receptors permanently switched on (e.g., mutant RAS, HER2 amplification).
2. Evading growth suppressors — they disable the brakes, most famously the RB and TP53 tumor suppressors.
3. Resisting cell death (apoptosis) — they block the built-in self-destruct program, often by overexpressing survival proteins like BCL-2 or losing p53.
4. Enabling replicative immortality — normal cells count divisions via shortening telomeres and eventually senesce; cancer cells reactivate telomerase to divide indefinitely.
5. Inducing angiogenesis — tumors larger than about 1–2 mm need new blood vessels, so they secrete VEGF to recruit vasculature.
6. Activating invasion and metastasis — the capability that turns a contained problem into a fatal one.

Two enabling characteristics make the hallmarks possible: genome instability and mutation (a "mutator phenotype" that generates the variation natural selection acts on) and tumor-promoting inflammation. Later additions include deregulating cellular energetics (the Warburg effect — cancers favor glycolysis even with oxygen available, exploited clinically by FDG-PET scans) and avoiding immune destruction (the basis of immune-checkpoint therapy). The 2022 update proposed further dimensions such as unlocking phenotypic plasticity and the influence of the microbiome.

The power of the framework is that it is a checklist of what a cancer must solve, and each solved problem is a potential drug target.

Oncogenes and Tumor Suppressor Genes

The genetic drivers of cancer sort into two opposite categories, and the distinction is one of the most testable ideas in medicine.

Oncogenes are mutated or overexpressed versions of normal growth-promoting genes (proto-oncogenes). Think of them as a stuck accelerator. A single activating mutation in one of the two gene copies is enough to contribute to cancer — they act in a dominant (gain-of-function) manner at the cellular level. Mechanisms include point mutations (e.g., KRAS G12D locking the protein in the "on" state), gene amplification (HER2/neu in breast cancer, MYCN in neuroblastoma), and chromosomal translocations (the BCR-ABL fusion of the Philadelphia chromosome in chronic myeloid leukemia). Because the abnormal protein is a specific, druggable target, oncogenes are the basis of targeted therapy — imatinib for BCR-ABL is the classic triumph.

Tumor suppressor genes are the brakes — genes that restrain proliferation, repair DNA, or trigger apoptosis. They act in a recessive (loss-of-function) manner: typically both copies must be knocked out for the brake to fail. This is Knudson's two-hit hypothesis, derived from retinoblastoma. In sporadic retinoblastoma a single cell must acquire two independent hits, so tumors are rare and unilateral and appear later. In hereditary retinoblastoma the child inherits one defective RB1 allele in every cell, so only one more somatic hit is needed — explaining early, bilateral, multifocal tumors. The master example is TP53 ("guardian of the genome"), lost in over half of all human cancers; its germline loss causes Li-Fraumeni syndrome. Other key suppressors: APC (colorectal cancer, gatekeeper of the adenoma–carcinoma sequence), BRCA1/BRCA2 (DNA repair; hereditary breast and ovarian cancer), and PTEN.

Feature	Oncogene	Tumor suppressor gene
Normal role	Promotes growth	Restrains growth / repairs DNA / triggers death
Analogy	Stuck accelerator	Failed brakes
Mutation type	Gain of function (activating)	Loss of function (inactivating)
Hits needed	One allele	Usually both alleles (two-hit)
Cellular behavior	Dominant	Recessive
Examples	RAS, MYC, HER2, BCR-ABL	TP53, RB1, APC, BRCA1/2, PTEN

A third, less emphasized class is the DNA repair genes (caretakers), such as the mismatch-repair genes mutated in Lynch syndrome; losing them accelerates the accumulation of mutations in the other two classes.

Worked example: the colorectal adenoma–carcinoma sequence

Fearon and Vogelstein's model of colon cancer is the textbook demonstration that carcinogenesis is stepwise and cumulative, not a single event. A normal colonic epithelial cell first loses APC (forming a small benign adenoma), then activates KRAS (adenoma enlarges), then loses further suppressors on chromosome 18 and finally TP53 (transition to invasive carcinoma). No single mutation makes cancer; it is the accumulated portfolio — accelerators pressed and brakes cut — that matters. This is also why cancer is largely a disease of aging: it takes years to collect the required hits.

Multistep Carcinogenesis and How Cancer Spreads

Classic experimental carcinogenesis divides the process into three phases. Initiation is an irreversible mutation from a carcinogen (a chemical, radiation, or virus) that primes a cell. Promotion is the reversible, prolonged proliferation of that initiated clone driven by promoters (hormones, chronic inflammation, tobacco smoke components) — this is where lifestyle and time matter and where prevention can intervene. Progression is the acquisition of further mutations, genomic instability, and malignant, invasive behavior.

The step that makes cancer lethal is metastasis — roughly 90% of cancer deaths result from metastases, not from the primary tumor. Metastasis is an inefficient, multistage cascade:

1. Local invasion — cells breach the basement membrane. Many undergo an epithelial-to-mesenchymal transition (EMT), losing E-cadherin cell–cell adhesion and gaining motility. They secrete matrix metalloproteinases (MMPs) to digest surrounding matrix.
2. Intravasation — tumor cells enter blood or lymphatic vessels.
3. Survival in circulation — most circulating tumor cells die from shear stress and immune attack; survivors may cluster with platelets for protection.
4. Arrest and extravasation — cells lodge in a distant capillary bed and cross into the tissue.
5. Colonization — the hardest step: forming a growing secondary tumor in a foreign microenvironment, often after a period of dormancy.

Metastatic spread is not random. In 1889 Stephen Paget proposed the "seed and soil" hypothesis: a tumor cell (seed) only grows where the microenvironment (soil) is hospitable. This explains characteristic patterns — prostate cancer to bone, colon cancer to liver (via portal drainage), lung cancer to brain. Lymphatic spread typically reaches regional nodes first (the basis of sentinel lymph node biopsy), while hematogenous spread favors sarcomas and certain carcinomas.

Real-World Applications

• Targeted therapy and precision oncology. Identifying the driver mutation lets us match drugs to tumors: trastuzumab for HER2-amplified breast cancer, imatinib for BCR-ABL CML, EGFR and ALK inhibitors in lung cancer, and PARP inhibitors that exploit the DNA-repair defect in BRCA-mutant tumors (synthetic lethality).
• Immunotherapy. Understanding the hallmark "avoiding immune destruction" produced checkpoint inhibitors (anti–PD-1, anti–CTLA-4) that release the immune brakes cancers exploit.
• Screening and prevention. The multistep model justifies screening: colonoscopy removes adenomas before they progress; HPV vaccination and cervical cytology interrupt cervical carcinogenesis; smoking cessation removes a promoter.
• Hereditary risk counseling. Germline testing for BRCA1/2, Lynch, and Li-Fraumeni genes guides risk-reducing surgery, intensified surveillance, and family testing.
• Diagnostics. FDG-PET imaging visualizes the Warburg effect; angiogenesis biology gave us anti-VEGF drugs like bevacizumab.

Common Mistakes

• "Cancer is a single disease with one cause." Wrong: it is hundreds of diseases defined by distinct driver mutations and tissues of origin. Correction: treatment and prognosis depend on the specific molecular subtype, which is why the same organ site can need completely different drugs.
• "One mutation causes cancer." Wrong: carcinogenesis is multistep and cumulative, requiring several driver alterations across oncogenes and tumor suppressors over years. Correction: this is exactly why cancer incidence rises steeply with age and why prevention (removing promoters) works.
• "Oncogenes and tumor suppressors are just two names for cancer genes." Wrong: they are mechanistically opposite. Oncogenes are dominant gain-of-function accelerators (one hit); tumor suppressors are recessive loss-of-function brakes (two hits). Correction: the distinction predicts inheritance patterns and drug strategy — you inhibit an oncoprotein but cannot easily "restore" a lost suppressor.
• "The primary tumor is what kills the patient." Wrong for most solid cancers: metastasis to vital organs is the usual cause of death. Correction: staging and much of therapy focus on detecting and preventing spread.
• "Benign tumors are just early cancers." Wrong: benign tumors do not invade or metastasize by definition; the invasive step is the biological line between benign and malignant.

Comparison and Connections

Concept	Benign tumor	Malignant tumor (cancer)
Growth	Slow, expansile	Often rapid, infiltrative
Border	Well-circumscribed, may be encapsulated	Irregular, invades locally
Basement membrane	Intact	Breached
Metastasis	Never	Yes
Differentiation	Well differentiated	Variable, often poorly differentiated

Related distinctions worth keeping straight: initiation vs promotion (irreversible mutation vs reversible proliferation), grade vs stage (how abnormal the cells look vs how far the cancer has spread), and carcinoma vs sarcoma vs leukemia/lymphoma (epithelial vs mesenchymal vs hematopoietic origin). Cancer biology connects tightly to the pathology of neoplasia, the pharmacology of chemotherapy, and immunology (tumor immunosurveillance and checkpoint control).

Practice Questions

Recall

Q: State Knudson's two-hit hypothesis and the gene it was derived from. A: Tumor suppressor genes require inactivation of both alleles to lose function; it was derived from statistical analysis of retinoblastoma and the RB1 gene, explaining why hereditary (one inherited hit) cases are early and bilateral while sporadic (two somatic hits) cases are late and unilateral.

Understanding

Q: Why does a single activating mutation suffice for an oncogene but not for a tumor suppressor? A: Oncogene mutations are gain-of-function and dominant — one hyperactive copy drives growth even with a normal second allele. Tumor suppressors are loss-of-function and recessive — a single remaining functional copy still provides the brake, so both must be lost.

Application

Q: A 3-year-old presents with bilateral retinal tumors and a family history of eye cancer. What is the likely genetic mechanism and what does it predict about the child's future risk? A: Hereditary retinoblastoma from a germline RB1 mutation (first hit inherited in every cell). Bilaterality reflects the need for only one further somatic hit. The child carries elevated lifetime risk of second primary cancers, notably osteosarcoma.

Analysis

Q: A patient's colon cancer is well controlled at the primary site but they die of liver failure from metastases. Explain, using the invasion–metastasis cascade and "seed and soil," why the liver was involved. A: Colonic tumor cells that acquired invasive capability (EMT, MMP secretion, loss of E-cadherin) intravasated into the portal venous drainage, which flows directly to the liver — a hospitable "soil" where surviving "seeds" colonized. Death from metastatic burden, not the primary, illustrates why metastasis dominates cancer mortality.

FAQ

Is all cancer inherited? No. The great majority (around 90–95%) of cancers are sporadic, arising from somatic mutations accumulated over a lifetime from environmental exposures, replication errors, and aging. Only a minority are hereditary syndromes from germline mutations, though those are important to identify for the whole family.

If cancer is genetic, why do lifestyle factors matter? Because lifestyle factors cause or promote the genetic changes. Tobacco, UV light, and certain infections act as initiators (mutagens) or promoters (driving proliferation of initiated cells). Prevention works by removing these drivers before enough hits accumulate.

Can we just "turn the good genes back on" to cure cancer? Restoring a lost tumor suppressor is far harder than inhibiting an overactive oncoprotein — you can block a hyperactive kinase with a drug, but reintroducing functional p53 into every tumor cell is technically difficult. This asymmetry is a major reason targeted therapies mostly hit oncogenes.

Why does chemotherapy cause side effects like hair loss and low blood counts? Traditional cytotoxic chemotherapy targets the hallmark of rapid proliferation, so it also damages normal fast-dividing tissues — hair follicles, bone marrow, and gut lining. Targeted and immune therapies aim to be more selective but bring their own toxicities.

What is the Warburg effect and why do PET scans use it? Cancer cells often rely on glycolysis for energy even when oxygen is available (deregulated energetics). Because they take up glucose avidly, a radiolabeled glucose analog (FDG) concentrates in tumors, lighting them up on PET imaging for staging and monitoring.

Do all cancers metastasize? Not necessarily during the patient's lifetime, but the capability to invade and metastasize is a defining hallmark of malignancy. Some cancers (e.g., basal cell carcinoma of skin) rarely metastasize despite being locally invasive.

Quick Revision

• Cancer = disorder of cell growth, death, and behavior driven by accumulated genetic/epigenetic changes.
• Hallmarks: sustained proliferation, evading suppressors, resisting death, replicative immortality (telomerase), angiogenesis, invasion/metastasis; enabled by genome instability and inflammation; plus altered energetics and immune evasion.
• Oncogenes = accelerators, gain-of-function, dominant, one hit (RAS, MYC, HER2, BCR-ABL).
• Tumor suppressors = brakes, loss-of-function, recessive, two hits (TP53, RB1, APC, BRCA1/2).
• Knudson two-hit explains hereditary vs sporadic retinoblastoma.
• Carcinogenesis is multistep: initiation (irreversible mutation) → promotion (reversible proliferation) → progression.
• Metastasis causes ~90% of cancer deaths: invade → intravasate → survive circulation → extravasate → colonize; "seed and soil" governs where.
• History: humoral theory → Virchow's cell theory → Pott/Rous carcinogens → somatic-mutation theory (Bishop & Varmus, Knudson) → Hanahan & Weinberg hallmarks.

Related Topics

Prerequisites

• Oncology branch overview
• Cell cycle, DNA replication and repair (see Biochemistry)
• Neoplasia and tumor pathology (see Pathology)

Related Topics

• Tumor immunology and immunosurveillance (see Immunology)
• Hereditary cancer syndromes (see Medical Genetics)

Next Topics

• Principles of cancer staging, grading, and diagnosis
• Chemotherapy, targeted therapy, and immunotherapy (see Pharmacology)